ProQR Therapeutics (NASDAQ:PRQR) Shares Purchased by Northern Trust Corp

Northern Trust Corp raised its holdings in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) by 2,550.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 417,398 shares of the biopharmaceutical company's stock after purchasing an additional 401,648 shares during the quarter. Northern Trust Corp owned 0.51% of ProQR Therapeutics worth $1,106,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Adage Capital Partners GP L.L.C. raised its holdings in shares of ProQR Therapeutics by 164.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock valued at $25,446,000 after acquiring an additional 5,976,813 shares in the last quarter. Affinity Asset Advisors LLC bought a new stake in shares of ProQR Therapeutics in the fourth quarter valued at about $7,486,000. Platinum Investment Management Ltd. bought a new stake in shares of ProQR Therapeutics in the fourth quarter valued at about $4,076,000. Altium Capital Management LLC bought a new stake in shares of ProQR Therapeutics in the fourth quarter valued at about $1,524,000. Finally, Walleye Capital LLC bought a new stake in shares of ProQR Therapeutics in the fourth quarter valued at about $1,196,000. 32.65% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on PRQR. Citigroup upgraded ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a report on Monday, March 10th. Chardan Capital reiterated a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Friday, March 14th. Cantor Fitzgerald began coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $8.00 target price on the stock. Oppenheimer cut their target price on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. Finally, Evercore ISI began coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $8.00.

ProQR Therapeutics Trading Up 7.2%

Shares of PRQR stock traded up $0.12 during trading hours on Monday, reaching $1.78. 306,013 shares of the company's stock were exchanged, compared to its average volume of 635,127. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.62. The stock has a market cap of $187.28 million, a PE ratio of -5.56 and a beta of 0.35. The stock's fifty day moving average price is $1.47 and its two-hundred day moving average price is $2.18.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. The business had revenue of $4.89 million for the quarter, compared to analysts' expectations of $4.90 million. On average, equities analysts expect that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).